Trial Profile
A Phase 2a, Open-Label Study to Evaluate the Safety, Pharmacokinetics and Efficacy of the Combination of AL-335 and Odalasvir, With or Without Simeprevir, in Treatment-Naïve Subjects With Genotype 1, 2 or 3 Chronic Hepatitis C Infection With or Without Compensated Child Pugh A Cirrhosis
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 17 Sep 2021
Price :
$35
*
At a glance
- Drugs Adafosbuvir (Primary) ; AL 335/odalasvir/simeprevir (Primary) ; Odalasvir (Primary) ; Simeprevir (Primary)
- Indications Hepatitis C
- Focus Adverse reactions
- Sponsors Alios BioPharma
- 02 Aug 2018 Results (n=112) published in the Hepatology.
- 20 Jul 2018 Status changed to completed.
- 06 Nov 2017 Planned primary completion date changed from 30 Dec 2017 to 30 Jun 2018.